Toujeo

Toujeo contains insulin glargine, a long-acting insulin analogue developed to support stable and consistent blood sugar control over a full 24-hour period. It is designed to provide a smooth, steady release profile that closely mimics the body’s natural background insulin activity. This long-duration action helps maintain balanced glucose levels throughout the day and night, reducing fluctuations and supporting overall metabolic stability.
Toujeo is formulated in a concentrated strength, allowing smaller injection volumes while delivering the same effective insulin support. This concentration can improve comfort and convenience for individuals who require higher daily insulin amounts. Its extended and even activity profile supports predictable glucose management, helping users maintain daily routines with greater confidence and fewer unexpected variations.
The insulin glargine formulation in Toujeo works by forming micro-precipitates in the subcutaneous tissue after injection. These slowly release insulin into the bloodstream, ensuring continuous basal coverage. This mechanism supports long-term glucose regulation and contributes to steady energy utilization throughout the day.
Toujeo is widely recognized for its consistency, reliability, and advanced formulation technology. It plays an important role in modern diabetes care by offering long-lasting support for glucose balance, improved daily stability, and a simplified routine for long-term metabolic management. Its design reflects a focus on precision, safety, and patient-centered innovation, making it a trusted option in long-acting insulin therapy worldwide.